# A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain

> **NCT06764186** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 101 (actual)

## Conditions studied

- Locally Advanced or Metastatic Breast Cancer

## Interventions

- **DRUG:** Fulvestrant
- **DRUG:** Capivasertib

## Key facts

- **NCT ID:** NCT06764186
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-07
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2026-04-08

## Collaborators

- Apices Soluciones S.L.
- SOLTI Breast Cancer Research Group

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06764186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06764186, "A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06764186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*